戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nts undergoing femoro-popliteal percutaneous transluminal angioplasty.
2 tents over bare metal stents or percutaneous transluminal angioplasty alone, particularly in long, he
3 strategies to treat atherosclerosis, such as transluminal angioplasty and stent implantation, often c
4 in the medical group versus the percutaneous transluminal angioplasty and stenting (PTAS) group (p=0.
5 increasingly being treated with percutaneous transluminal angioplasty and stenting (PTAS) to prevent
6                RECENT FINDINGS: Percutaneous transluminal angioplasty and stenting is a treatment opt
7  are not randomized and receive percutaneous transluminal angioplasty and stenting or femoropopliteal
8 gh-quality observational data on the role of transluminal angioplasty and stenting, submaximal balloo
9 ither femoropopliteal bypass or percutaneous transluminal angioplasty and stenting; patients with TAS
10 temporary studies of the use of percutaneous transluminal angioplasty as primary treatment for patien
11                    Two balloon (percutaneous transluminal angioplasty) catheters were used.
12 s (2005-2015) on the effects of percutaneous transluminal angioplasty for the treatment of infrapopli
13        Contemporary outcomes of percutaneous transluminal angioplasty for the treatment of infrapopli
14 asty group and the conventional percutaneous transluminal angioplasty group had similar primary paten
15 gh 12 months were higher in the percutaneous transluminal angioplasty group.
16           At many institutions, percutaneous transluminal angioplasty has become the treatment of cho
17                      Peripheral percutaneous transluminal angioplasty is fraught with a substantial r
18  peripheral artery disease with percutaneous transluminal angioplasty is limited by the occurrence of
19 pectoris when bypass surgery or percutaneous transluminal angioplasty is not indicated.
20                        Standard percutaneous transluminal angioplasty is the current recommended trea
21 sions <80 mm underwent percutaneous coronary transluminal angioplasty, laser ablation, and/or rotatio
22 lihood of technical success for percutaneous transluminal angioplasty of dialysis access venous steno
23 ty, and clinical progression to percutaneous transluminal angioplasty or loss of patency during 12-mo
24 ion bias were observed for most percutaneous transluminal angioplasty outcomes.
25  After successful high-pressure percutaneous transluminal angioplasty, participants were randomly ass
26 el DCB (n = 1,837) and uncoated percutaneous transluminal angioplasty (PTA) (n = 143) were included.
27 th critical limb ischemia using percutaneous transluminal angioplasty (PTA) and bail-out bare metal s
28 and reintervention rates versus percutaneous transluminal angioplasty (PTA) and improve wound healing
29   The RCT compared the DES with percutaneous transluminal angioplasty (PTA) and provisional bare-meta
30 h a low-dose DCB or an uncoated percutaneous transluminal angioplasty (PTA) balloon.
31 accesses that underwent balloon percutaneous transluminal angioplasty (PTA) between January 2009 and
32 CBA) compared with conventional percutaneous transluminal angioplasty (PTA) for below-the-knee arteri
33 ng balloons versus conventional percutaneous transluminal angioplasty (PTA) for the reduction of rest
34  paclitaxel-coated balloon with percutaneous transluminal angioplasty (PTA) for the treatment of symp
35 CB) angioplasty versus standard percutaneous transluminal angioplasty (PTA) in patients with femoropo
36                                 Percutaneous transluminal angioplasty (PTA) is the standard therapy f
37                                 Percutaneous transluminal angioplasty (PTA) of stenotic arteriovenous
38 esions that are not amenable to percutaneous transluminal angioplasty (PTA) or for recurrence after P
39    Use of a covered stent after percutaneous transluminal angioplasty (PTA) was compared to PTA alone
40 her (all P<.001) than those for percutaneous transluminal angioplasty (PTA), as were radiation exposu
41 compare long-term outcomes with percutaneous transluminal angioplasty (PTA), stent placement, atherec
42 mortality after DCB or uncoated percutaneous transluminal angioplasty (PTA), we aggregated data from
43 omes compared with conventional percutaneous transluminal angioplasty (PTA), yet durability of the tr
44 d the patency rate of SFA after percutaneous transluminal angioplasty (PTA).
45 n renal function at the time of percutaneous transluminal angioplasty (PTA).
46 .PACT Admiral Paclitaxel-Coated Percutaneous Transluminal Angioplasty [PTA] Balloon Catheter vs Stand
47 n=200) or standard angioplasty (percutaneous transluminal angioplasty [PTA]) (n=100).
48 ating vascular restenosis after percutaneous transluminal angioplasty remains a formidable challenge.
49 ns include balloon angioplasty (percutaneous transluminal angioplasty [standard], drug-coated balloon
50 avian-carotid bypass and 5 with percutaneous transluminal angioplasty stenting of the subclavian).
51          In the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS), early recurren
52  results of the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS).
53 ventions after femoro-popliteal percutaneous transluminal angioplasty up to 1 year of follow-up.
54 fully undergone angiography and percutaneous transluminal angioplasty using CO2 as the sole contrast
55                                 Percutaneous transluminal angioplasty was then performed in 18 of the
56 erosclerotic disease undergoing percutaneous transluminal angioplasty were randomized to paclitaxel-c
57 teal peripheral artery disease, percutaneous transluminal angioplasty with a paclitaxel-coated balloo